Skip to main content
. 2012 May 15;67(7):858–868. doi: 10.1111/j.1398-9995.2012.02833.x

Table 1.

Specification of drugs used in this study

Name Synonym Supplier Main target(s)
Bosutinib SKI-606 ChemieTek ABL, SRC
Dasatinib BMS-354825 ChemieTek ABL, SRC, KIT, BTK, LYN
Erlotinib OSI-774 ChemieTek EGFR, Her2
Gefitinib ZD1389 ChemieTek EGFR, Her2
Imatinib STI-571 ChemieTek ABL, KIT, PDGFR
Lapatinib GW572016 ChemieTek EGFR, Her2
Masitinib AB1010 LC Laboratories KIT, PDGFR, LYN
Midostaurin PKC412 LC Laboratories FLT3, KIT
Nilotinib AMN107 ChemieTek ABL, KIT, PDGFR
Sorafenib BAY 43-9006 ChemieTek Raf, VEGFR, KIT
Sunitinib SU11248 ChemieTek PDGFR, VEGFR, KIT
Everolimus RAD001 ChemieTek mTOR
NVP-BEZ235 BEZ235 ChemieTek mTOR, PI3 kinase
Tozasertib VX-680, MK-0457 ChemieTek Aurora Kinase A, KIT
Vorinostat SAHA ChemieTek HDAC

BTK, Bruton's tyrosine kinase; EGFR, epidermal growth factor receptor; PDGFR, platelet-derived growth factor receptor; VEGFR, vascular endothelial growth factor receptor; mTOR, mammalian target of rapamycin; PI3 kinase, phosphoinositide 3 kinase; HDAC, histone deacetylase.